Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
JAMA Psychiatry. 2021 Jun 1;78(6):607-615. doi: 10.1001/jamapsychiatry.2020.4783.
Patients coping with rare diseases need psychosocial support.
To evaluate the efficacy of a brief, transdiagnostic, peer-delivered intervention for patients with rare diseases in addition to care as usual (CAU) compared with CAU only.
DESIGN, SETTING, AND PARTICIPANTS: In this 2-group randomized clinical trial conducted from October 5, 2017, to July 12, 2019, patients were recruited via specialized clinics and patient organizations across Germany and participated from home. The study included consecutive adult patients with neurofibromatosis type 1, Marfan syndrome, primary sclerosing cholangitis, and pulmonary arterial hypertension who have limited functionality because of the disease. Exclusion criteria were a life-threatening health status and ongoing psychotherapeutic treatment. Of 143 patients screened for eligibility with a semistructured telephone interview, 54 were excluded, and 89 were randomized: 45 patients were randomly allocated to the peer-delivered intervention group, and 44 to the control group; 87 patients (98%) completed the 6-month follow-up assessment. The analysis was performed using an intention-to-treat principle. Data cleansing and analysis were conducted between April 25, 2019, and February 13, 2020.
The 6-week intervention consisted of a self-help book and telephone-based peer counseling in addition to CAU. The control group received CAU alone. Peer counselors received training, structured consultation guidelines, and supervision.
The primary outcome was acceptance of the disease as assessed using the Illness Cognition Questionnaire (ICQ; mean sum scores range from 0 to 18, with higher values representing more acceptance) 6 months after the intervention. Secondary outcomes included self-reported coping strategies (Health Education Impact Questionnaire), illness cognition (ICQ and Illness Perception Questionnaire), depression severity (Patient Health Questionnaire 9-item depression scale), anxiety severity (Generalized Anxiety Disorder Scale), quality of life (12-Item Short-Form Health Survey), and social support (Social Support Questionnaire). Outcomes were assessed before the intervention, after the intervention, and at a 6-month follow-up.
The mean (SD) age of the 89 participating patients was 46.3 (14.9) years; 59 (66%) were women. There were no group differences regarding baseline variables. All patients allocated to the intervention group completed the intervention. Six months after the intervention, but not directly after completing the program, the intervention group had significantly higher rates of acceptance (ICQ) of the disease (primary outcome) compared with the CAU group. Mean (SD) baseline ICQ scores were 9.61 (3.79) in the control group and 9.86 (3.40) in the intervention group. Mean (SE) ICQ scores at 6 months were 10.32 (0.42) for the control group and 11.79 (0.42) for the intervention group, with a significant mean difference of -1.47 (95% CI, -2.63 to -0.31; P = .01). Several secondary outcomes, including different coping strategies, social support, and mental quality of life, were significantly higher after the intervention compared with the control group.
In this randomized clinical trial, a self-help and peer counseling intervention improved patients' acceptance of their rare chronic diseases. Self-management and peer support can efficiently address the unique care needs of patients with rare diseases.
isrctn.org Identifier: ISRCTN13738704.
患有罕见疾病的患者需要心理社会支持。
评估一种简短的、跨诊断的、同伴提供的干预措施对除了常规护理(CAU)之外的罕见疾病患者的疗效,与仅接受 CAU 的患者相比。
设计、地点和参与者:这是一项 2 组随机临床试验,于 2017 年 10 月 5 日至 2019 年 7 月 12 日进行,参与者通过德国的专门诊所和患者组织招募,并在家中参与。该研究纳入了患有神经纤维瘤病 1 型、马凡综合征、原发性硬化性胆管炎和肺动脉高压的成年患者,这些患者由于疾病而功能受限。排除标准是危及生命的健康状况和正在进行的心理治疗。在通过半结构化电话访谈筛选出 143 名符合条件的患者中,有 54 名被排除,89 名被随机分配:45 名患者被随机分配到同伴提供的干预组,44 名患者被分配到对照组;87 名患者(98%)完成了 6 个月的随访评估。分析采用意向治疗原则。数据清理和分析于 2019 年 4 月 25 日至 2020 年 2 月 13 日进行。
为期 6 周的干预包括自我帮助手册和基于电话的同伴咨询,外加 CAU。对照组仅接受 CAU。同伴咨询师接受了培训、结构化咨询指南和监督。
主要结果是在干预后 6 个月使用疾病认知问卷(ICQ;平均总分范围为 0 至 18,得分越高表示接受程度越高)评估疾病的接受程度。次要结果包括自我报告的应对策略(健康教育培训影响问卷)、疾病认知(ICQ 和疾病感知问卷)、抑郁严重程度(患者健康问卷 9 项抑郁量表)、焦虑严重程度(广泛性焦虑症量表)、生活质量(12 项简明健康调查)和社会支持(社会支持问卷)。结果在干预前、干预后和 6 个月随访时进行评估。
89 名参与患者的平均(SD)年龄为 46.3(14.9)岁;59 名(66%)为女性。两组在基线变量方面没有差异。所有被分配到干预组的患者都完成了干预。在干预 6 个月后,但不是直接在完成项目后,干预组对疾病的接受程度(主要结果)明显高于 CAU 组。对照组的基线 ICQ 得分平均(SD)为 9.61(3.79),干预组为 9.86(3.40)。对照组 6 个月时的平均(SE)ICQ 得分为 10.32(0.42),干预组为 11.79(0.42),平均差异显著为-1.47(95%置信区间,-2.63 至-0.31;P=0.01)。与对照组相比,几个次要结果,包括不同的应对策略、社会支持和心理健康质量,在干预后显著提高。
在这项随机临床试验中,自我帮助和同伴咨询干预措施提高了患者对其罕见慢性疾病的接受程度。自我管理和同伴支持可以有效地满足罕见疾病患者的独特护理需求。
isrctn.org 标识符:ISRCTN13738704。